BRCA1 and breast carcinoma: To test this possibility, we treated the BRCA1/2-proficient breast cancer cell lines HS578T and MDA-MB-231 with TRDMT1i and either PARPi (Olaparib) or POLθi (Novobiocin) (Fig. 6b, c)50.